Guangdong Zhaotai InVivo Biomedicine

Guangdong Zhaotai InVivo Biomedicine is a clinical-stage biotechnology company based in Guangzhou, China, specializing in the development of next-generation cell therapies for oncology. As a subsidiary of Hunan Zhaotai Medical Group, the company focuses on advancing third and fourth-generation CAR-T cell technologies and engineered Tumor-Infiltrating Lymphocyte (TIL) therapies. Their lead program, 1928zT2, is a novel CD19-targeted CAR-T therapy incorporating a TLR2 signaling domain, which has shown promising results in treating B-cell malignancies with central nervous system involvement. The company's extensive pipeline also targets solid tumor antigens such as CLDN18.2, ROR1, and GPC3 using innovative CAR-TIL and chimeric switch receptor platforms. Guangdong Zhaotai InVivo Biomedicine maintains strategic collaborations with the Guangzhou Institutes of Biomedicine and Health (GIBH) and major clinical centers to accelerate the translation of its immunotherapy portfolio.